| Item |
Information |
|
Drug Groups
|
approved; investigational |
|
Description
|
An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [PubChem] |
| Indication |
For the treatment of epilepsy and pain associated with true trigeminal neuralgia. |
| Pharmacology |
Carbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia. |
| Toxicity |
Mild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic |
| Half Life |
25-65 hours |
| Protein Binding |
Carbamazepine in blood is 76% bound to plasma proteins. |
| External Links |
|